A Safety run-in and Phase II Study of Epacadostat in Combination With Radiation Therapy and Avelumab in Patients With Recurrent Gliomas
Status: Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary) ; Bevacizumab (Primary) ; Epacadostat (Primary)
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 31 Oct 2019 Planned End Date changed from 30 Aug 2024 to 31 Jan 2025.
- 31 Oct 2019 Planned primary completion date changed from 31 May 2022 to 31 Oct 2022.
- 31 Oct 2019 Planned initiation date changed from 30 Aug 2019 to 31 Jan 2020.